SomaNautix is developing an internal pipeline of Precision Medicines in oncology. The objective is to dramatically improve the therapeutic index of chemo- and immuno-therapies by targeting tumour cells only
Peritoneal carcinomatosis (PC) is a metastatic invasion of tumour cells into the lining within the abdominal cavity and the intra-abdominal organs PC is a rare primary tumour and 60% of gastric, 40% of ovarian and 35% of colon malignancies. Median survival is generally one to three months. It is proposed to treat tumours with a balanced combination of chemotherapy and immune-modulation followed by priming the immune system with a "find and kill-me" signal to attack tumour metastasis.
Poor and inefficient drug delivery is a major reason for therapeutic failure in childhood brain tumours. The integrity of the blood-brain barrier (BBB) may render some paediatric tumours (e.g. diffuse midline gliomas) totally resistant to drug therapy, where the BBB (e.g. medulloblastoma and ependymoma) is partially disrupted this is also true. High doses of systemic chemotherapy are also required which result in significant and dose limiting side effects. Therefore, improving drug transport across the BBB in a tumour specific manner could potentially result in both improved survival and also reduce systemic toxicity. SMX002 will be a super-selective carrier equipped to target selective passage across the BBB, following glucose gradients, binding to neoplastic cells and with the ability to deliver combinations of anticancer drugs. Crossing the BBB will be validated by targeting both low density lipoprotein receptor-related protein 1 (LRP1) and glucose transporters (GLUT1) combined with tumour specific targeting motifs to create super-selective binding initially in paediatric diffuse gliomas.